Shares in Singapore and California, USA-based biotech ASLAN Pharmaceuticals (Nasdaq: ASLN) have fallen by a quarter as traders pore over mid-stage data for lead candidate eblasakimab.
The top-line results show the Phase IIb dose-ranging study met its primary endpoint, a measure of efficacy in treating adults with moderate-to-severe atopic dermatitis (AD).
However, the data also show a high response from the placebo arm, a factor which appears to have confused the picture somewhat.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze